

Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/RB05BF1B15BEN.html>

Date: May 2020

Pages: 53

Price: US\$ 125.00 (Single User License)

ID: RB05BF1B15BEN

Abstracts

Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The company's manufacturing services include contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm's development and technology services supports customers from initial product concept to the approved commercial pharmaceutical drug. It includes services such as raw material supply, formulation, validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, Portugal, India, Israel and the US. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB Key Recent Developments

May 07,2020: Recipharm publishes its interim report January-March 2020

May 07,2020: Recipharm secures supply of drug substance and commences manufacture of chloroquine phosphate

Apr 08,2020: Recipharm's board of directors decides to withdraw dividend proposal

Mar 06,2020: Recipharm completes delisting of Consort Medical

Mar 06,2020: Recipharm notes an increased demand for Chloroquine Phosphate

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Recipharm AB - Key Facts
Recipharm AB - Key Employees
Recipharm AB - Key Employee Biographies
Recipharm AB - Major Products and Services
Recipharm AB - History
Recipharm AB - Company Statement
Recipharm AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Recipharm AB - Business Description
Business Segment: D&T
Overview
Performance
Business Segment: MFG-SI
Overview
Performance
Business Segment: MFG-SO
Overview
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: India
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Other
Performance
Geographical Segment: Portugal
Performance

Geographical Segment: Spain
Performance
Geographical Segment: Sweden
Performance
Geographical Segment: UK
Performance
Recipharm AB - Corporate Strategy
Recipharm AB - SWOT Analysis
SWOT Analysis - Overview
Recipharm AB - Strengths
Recipharm AB - Weaknesses
Recipharm AB - Opportunities
Recipharm AB - Threats
Recipharm AB - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Recipharm AB, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 07, 2020: Recipharm publishes its interim report January-March 2020
May 07, 2020: Recipharm secures supply of drug substance and commences manufacture of chloroquine phosphate
Mar 06, 2020: Recipharm completes delisting of Consort Medical
Mar 06, 2020: Recipharm notes an increased demand for Chloroquine Phosphate
Feb 20, 2020: Recipharm publishes report for the fourth quarter and full year 2019
Feb 07, 2020: Recipharm announces that Consort Medical applies for delisting

Feb 05, 2020: Consort Medical becomes part of the Recipharm Group

Dec 09, 2019: Recipharm invests in its US inhalation development service

Nov 18, 2019: Recipharm to communicate new financial targets on Capital Markets Day

Nov 14, 2019: Recipharm joins the AMR Industry Alliance

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Recipharm AB, Key Facts
Recipharm AB, Key Employees
Recipharm AB, Key Employee Biographies
Recipharm AB, Major Products and Services
Recipharm AB, History
Recipharm AB, Other Locations
Recipharm AB, Subsidiaries
Recipharm AB, Key Competitors
Recipharm AB, Ratios based on current share price
Recipharm AB, Annual Ratios
Recipharm AB, Annual Ratios (Cont...1)
Recipharm AB, Annual Ratios (Cont...2)
Recipharm AB, Interim Ratios
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Recipharm AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Recipharm AB, Performance Chart (2015 - 2019)

Recipharm AB, Ratio Charts

Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Vetter Pharma-Fertigung GmbH & Co KG

Patheon NV

Iconovo AB

Fareva SA

F. Hoffmann-La Roche Ltd

Corden Pharma International GmbH

Catalent Inc

Boehringer Ingelheim International GmbH

I would like to order

Product name: Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/RB05BF1B15BEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RB05BF1B15BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970